Tenelia Triple Combination Study

PHASE3CompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

October 31, 2017

Study Completion Date

December 31, 2017

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Teneligliptin

Subjects will visit the center on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.

Trial Locations (1)

Unknown

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Handok Inc.

INDUSTRY